| SUBJECT: | ACADEMIC AFFAIRS | TITLE: | HUMAN RESEARCH SUBJECTS: MEDICAL CARE |
| CODING: | 00-01-20-85:00 | ADOPTED: | 07/01/87 | AMENDED: | 05/07/99 |
I. PURPOSE
To set policy
concerning medical care for human subjects who sustain physical injury
or illness as a direct result
of research
conducted under the auspices of the University.
II. ACCOUNTABILITY
Under the direction
of the Senior Vice President for Academic Affairs, the Deans and the Vice
Presidents of
the patient
care units shall ensure compliance with, and the Research Deans shall implement
this policy.
III. APPLICABILITY
This policy applies
to all research involving human subjects except those categories of research
that are
specifically
exempted in 46.101(b) of Part 46 of Volume 45 Code of Federal Regulations
(45 CFR Part 46),
Subpart A, "Protection
of Human Subjects."
IV. POLICY
A.
The University shall comply with all the provisions of 45 CFR Part 46,
Subpart A. In accordance with
section 46.116 of these regulations and allowing for the potential exceptions
provided for in paragraphs (c) and
(d) in this section, the following policies shall apply to all human subjects
participating in research involving
more than minimal risk of harm:
1. For those human subjects who sustain physical injury
or illness as a direct result of participation in a research
project conducted under the auspices of the University, the Principal Investigator
of the research project
shall take the following actions:
a. arrange for the hospital admission and/or outpatient
treatment of the injured subject which shall
take place, if practicable, at a University-owned or University-affiliated
patient care unit.
b. immediately notify the Research Dean, the Dean, the
Vice President of the patient care unit,
and the IRB Chair.
2. The Research Dean, in consultation with the Dean and
the Vice President of the patient care unit, shall
arrange for a review to determine whether the injury or illness is the
direct result of participation in the
research.
The review may be accomplished by two or more independent assessments by
faculty members appointed
by the Dean. These faculty shall not have any involvement with the research
in question but may be
members of the IRB that reviewed and approved the original research protocol.
Whenever possible, i.e., in
non-emergency situations, this review shall take place prior to hospitalization
and/or outpatient treatment of
the subject.
The Research Dean shall inform the Dean and the Vice President of the patient
care unit, the IRB Chair, the
Senior Vice President for Academic Affairs, and the Director of the University's
Office of Risk and Claims
Management about the results of this review, and about the hospitalization
and/or outpatient treatment of the
injured subject.
3. Third-party payers, if any, shall always be billed
first for the costs of the hospitalization and/or outpatient
treatment provided to those subjects who sustain physical injury or illness
as a direct result of
participation in a research project.
4. For research designed to test an investigational practice
(diagnostic, therapeutic or preventive drug or
device) where there is an industrial sponsor (such as a pharmaceutical
company), the Principal Investigator is
required to obtain from the sponsor a written statement:
(a) indemnifying and holding harmless the researchers,
the University, and the University's
employees and agents in the event of injury or illness in a research subject
as a direct result of
participation in the research protocol, and
(b) stipulating that the sponsor shall reimburse the
University for any and all reasonable and
necessary medical and/or dental expenses incurred by research subjects
taking part in the
protocol which are due to injury from the research set forth in the protocol,
but
(c) excepting situations where the injury results from
negligence by the University, its employees
or agents; where there is malfeasance by the University, its employees
or agents; and when there
is deviation from the research protocol.
The Research Deans shall ensure that such statements are obtained before the research may commence.
B.
All consent forms provided to research subjects participating in
research involving more than minimal risk
shall contain the following information:
1. For research on normal healthy volunteers:
"Participants in this study will be exposed to certain risks of physical
injury, which include:"
(provide a complete description if not provided elsewhere in the consent
form, or refer reader to
appropriate section of form). "In addition, it is possible that during
the course of these studies,
new adverse effects of" (fill in name of drug, device, procedure, etc.)
"that result in physical injury
may be discovered. Medical and/or dental treatment will be arranged by
UMDNJ for participants
who sustain physical injuries or illnesses as a direct consequence of participation
in the research.
The subject's health insurance carrier or other third-party payer will
be billed for the cost of this
treatment. No additional financial compensation is available."
Any exception to this statement must be approved by the Dean, the Vice
President of the patient care unit and
the Director of Risk and Claims Management.
2. For research on patients with a disease or medical
condition: "Participants in this study will be exposed to
certain risks of physical injury in addition to those associated with standard
forms of treatment, which include:"
(provide a complete description if not provided elsewhere in the consent
form, or refer reader to appropriate
section of form). "In addition, it is possible that during the course of
these studies, new adverse effects of" (fill
in name of drug, device, procedure, etc.) "that result in physical injury
may be discovered. Medical and/or
dental treatment will be arranged by UMDNJ for participants who sustain
physical injuries or illnesses as a
direct consequence of participation in the research. The subject's health
insurance carrier or other third-party
payer will be billed for the cost of this treatment. No additional financial
compensation is available."
Any exception to this statement must be approved by the Dean, the Vice
President of the patient care unit and
the Director of Risk and Claims Management.
3. For single-patient-treatment/compassionate-use protocols:
"Participants in this study will be exposed to certain risks of physical
injury in addition to those associated with
standard forms of therapy, which include:" (provide a complete description
if not provided elsewhere in the
consent form, or refer reader to appropriate section of form). "In addition,
it is possible that during the course
of these studies, new adverse effects of" (fill in name of drug, device,
procedure, etc.) "that result in physical
injury may be discovered. Medical and/or dental treatment will be arranged
by UMDNJ for participants who
sustain physical injuries or illnesses as a direct consequence of participation
in the research. The subject's
health insurance carrier or other third-party payer will be billed for
the cost of this treatment. Any costs not
covered by the insurance carrier or other third-party payer will be solely
at the expense of the subject. No
additional financial compensation is available."
Any exception to this statement must be approved by the Dean, the Vice
President of the patient care unit and
the Director of Risk and Claims Management
By Direction of the President:
_______________________________
Vice President for Academic Affairs